Since the start of the millennium, podcasts have gone from nonexistent to numbering in the millions, and Edison Research ...
Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based ...
Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ...
Over the last year, Viatris has been busy working to resolve FDA concerns at a critical drug manufacturing plant in India ...
The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...
While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...
A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation (NBDF) for a ...
Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities. ...
Chinese assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, ...
GenEdit is sailing toward the clinic with a new name and fresh funding. | GenEdit is sailing toward the clinic with a new ...
The committee’s reputation has taken a nosedive, however, following HHS Secretary Robert F. Kennedy Jr.’s decision to purge ...
As one long-running feud over the controversial generic drug carveout known as “skinny” labeling comes to a close, the United States’ top lawyer is urging the Supreme Court to reverse a recent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results